Evidence map›Paper›PMID 26684197›Full record

ArticlePloS one2015

Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.

Hélène Bonsang-Kitzis, Léonor Chaltier, Lisa Belin, Alexia Savignoni, Roman Rouzier, Marie-Paule Sablin, Florence Lerebours, François-Clément Bidard, Paul Cottu, Xavier Sastre-Garau and 3 more

Erratum issuedAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Gender Differences in Obesity-Related Cancers.Current obesity reports · 2021
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Peculiarities of the obese patient with cancer: a national consensus statement by the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2017
    Article
  17. Review
  18. Obesity and cancer: inflammation bridges the two.Current opinion in pharmacology · 2016
    Review
  19. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Hélène Bonsang-KitzisDepartment of Surgery, Institut Curie, Paris, France.
Léonor ChaltierDepartment of Biostatistic, Institut Curie, Paris, France.
Lisa BelinDepartment of Biostatistic, Institut Curie, Paris, France.
Alexia SavignoniDepartment of Biostatistic, Institut Curie, Paris, France.
Roman RouzierDepartment of Surgery, Institut Curie, Paris, France.
Marie-Paule SablinDepartment of Medical Oncology, Institut Curie, Paris, France.
Florence LereboursDepartment of Medical Oncology, Institut Curie, Paris, France.
François-Clément BidardDepartment of Medical Oncology, Institut Curie, Paris, France.
Paul CottuDepartment of Medical Oncology, Institut Curie, Paris, France.
Xavier Sastre-GarauDepartment of Tumor Biology, Institut Curie, Paris, France.
Marick LaéDepartment of Tumor Biology, Institut Curie, Paris, France.
Jean-Yves PiergaDepartment of Medical Oncology, Institut Curie, Paris, France.
Fabien ReyalDepartment of Surgery, Institut Curie, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTriple-negative breast cancers (TNBC) are a specific subtype of breast cancers with a particularly poor prognosis. However, it is a very heterogeneous subgroup in terms of clinical behavior and sensitivity to systemic treatments. Thus, the identification of risk factors specifically associated with those tumors still represents a major challenge. A therapeutic strategy increasingly used for TNBC patients is neoadjuvant chemotherapy (NAC). Only a subset of patients achieves a pathologic complete response (pCR) after NAC and have a better outcome than patients with residual disease. PURPOSE: The aim of this study is to identify clinical factors associated with the metastatic-free survival in TNBC patients who received NAC.

methodsWe analyzed 326 cT1-3N1-3M0 patients with ductal infiltrating TNBC treated by NAC. The survival analysis was performed using a Cox proportional hazard model to determine clinical features associated with prognosis on the whole TNBC dataset. In addition, we built a recursive partitioning tree in order to identify additional clinical features associated with prognosis in specific subgroups of TNBC patients.

resultsWe identified the lymph node involvement after NAC as the only clinical feature significantly associated with a poor prognosis using a Cox multivariate model (HR = 3.89 [2.42-6.25], p<0.0001). Using our recursive partitioning tree, we were able to distinguish 5 subgroups of TNBC patients with different prognosis. For patients without lymph node involvement after NAC, obesity was significantly associated with a poor prognosis (HR = 2.64 [1.28-5.55]). As for patients with lymph node involvement after NAC, the pre-menopausal status in grade III tumors was associated with poor prognosis (HR = 9.68 [5.71-18.31]).

conclusionThis study demonstrates that axillary lymph node status after NAC is the major prognostic factor for triple-negative breast cancers. Moreover, we identified body mass index and menopausal status as two other promising prognostic factors in this breast cancer subgroup. Using these clinical factors, we were able to classify TNBC patients in 5 subgroups, for which pre-menopausal patients with grade III tumors and lymph node involvement after NAC have the worse prognosis.

Indexed as

AdultAgedAntineoplastic AgentsAxillaBody Mass IndexCarcinoma, Ductal, BreastChemotherapy, AdjuvantFemaleHumansLymphatic MetastasisLymph NodesMenopauseMiddle AgedNeoadjuvant TherapyPrognosisSurvival AnalysisAntineoplastic Agents

Identifiers

PMID26684197
PMCPMC4686172

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.